lonafarnib has been researched along with Liver Neoplasms in 4 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 1 (25.00) | 29.6817 |
| 2010's | 3 (75.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, D; Huang, Y; Lian, Y; Wang, J; Wei, H; Zeng, G | 1 |
| Elazar, M; Glenn, JS | 1 |
| Barreiro, P; Sherman, KE; Soriano, V | 1 |
| Baum, C; Hollywood, E; Ilson, D; Kelsen, DP; Kemeny, N; O'Reilly, E; Saltz, LB; Sharma, S; Statkevich, P; Zaknoen, S; Zhu, Y | 1 |
2 review(s) available for lonafarnib and Liver Neoplasms
| Article | Year |
|---|---|
Emerging concepts for the treatment of hepatitis delta.
Topics: Animals; Antiviral Agents; Hepatitis B; Hepatitis B virus; Hepatitis D; Hepatitis D, Chronic; Hepatitis Delta Virus; Humans; Interferon-alpha; Lipopeptides; Liver Cirrhosis; Liver Neoplasms; Mice; Piperidines; Pyridines | 2017 |
Hepatitis delta and HIV infection.
Topics: Antiviral Agents; Disease Transmission, Infectious; Hepatitis D, Chronic; HIV Infections; Humans; Interferon-alpha; Lipopeptides; Liver Cirrhosis; Liver Neoplasms; Piperidines; Pyridines; Sustained Virologic Response | 2017 |
1 trial(s) available for lonafarnib and Liver Neoplasms
| Article | Year |
|---|---|
A phase II trial of farnesyl protein transferase inhibitor SCH 66336, given by twice-daily oral administration, in patients with metastatic colorectal cancer refractory to 5-fluorouracil and irinotecan.
Topics: Administration, Oral; Adult; Aged; Aged, 80 and over; Biopsy, Needle; Colorectal Neoplasms; Dose-Response Relationship, Drug; Drug Administration Schedule; Drug Resistance; Drug Resistance, Neoplasm; Enzyme Inhibitors; Female; Fluorouracil; Follow-Up Studies; Humans; Liver Neoplasms; Lung Neoplasms; Male; Middle Aged; Neoplasm Staging; Piperidines; Pyridines; Survival Analysis; Treatment Outcome | 2002 |
1 other study(ies) available for lonafarnib and Liver Neoplasms
| Article | Year |
|---|---|
The combination of lonafarnib and sorafenib induces cyclin D1 degradation via ATG3-mediated autophagic flux in hepatocellular carcinoma cells.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Autophagy; Autophagy-Related Proteins; Carcinoma, Hepatocellular; Cell Proliferation; Cyclin D1; Enzyme Inhibitors; Farnesyltranstransferase; Female; Gene Knockdown Techniques; Hep G2 Cells; Humans; Liver Neoplasms; Mice; Mice, Nude; Models, Biological; Piperidines; Protein Kinase Inhibitors; Proteolysis; Pyridines; Sorafenib; Ubiquitin-Conjugating Enzymes; Xenograft Model Antitumor Assays | 2019 |